Asset Details
Do you wish to reserve the book?
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Do you wish to request the book?
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
2003
Overview
The objective of the present study was to validate the use of intralesional injection of interleukin-2 (IL-2) in patients with skin and soft-tissue melanoma metastases. A total of 24 patients with AJCC stage III or IV melanoma and single or multiple skin and soft-tissue metastases were included. Interleukin-2 injections were administered intralesionally into the total number of cutaneous and soft-tissue metastases accessible from the skin, 2–3 times weekly, over 1–57 weeks. Single doses varied from 0.6 to 6 × 10
6
IU, depending on lesion size. The clinical response was monitored by sonography and confirmed by histopathology; response evaluation was confined to the intralesionally treated tumours. Complete response (CR) of the treated metastases was achieved in 15 patients (62.5%), the longest remission lasting 38 months to date. In five patients, partial response (PR) was achieved (21%) and in another three patients, progressive disease was observed (one patient not assessable). A total of 245 metastases were treated with CR in 209 (85%), and PR in 21 (6%). The therapy was generally well tolerated; the observed adverse events were mainly of grade 1–2 severity. Immunohistochemical studies showed the tumour cells undergoing apoptosis and revealed a mixed character of the inflammatory infiltrate. The unusual high CR rate in metastatic melanoma of 62.5% and the limited toxicity suggest that treatment of skin and soft-tissue melanoma metastases with intralesional injection of IL-2 may be a safe and effective alternative to conventional therapies. The optimal dosage and duration of this therapy still remain to be defined in larger prospective multicentre trials.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Aged
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Clinical
/ Female
/ Humans
/ Interleukin-2 - therapeutic use
/ Male
/ Oncology
/ Pharmacology. Drug treatments
/ Skin Neoplasms - drug therapy
/ Soft Tissue Neoplasms - drug therapy
/ Soft Tissue Neoplasms - pathology
